Renasant Bio, a Berkeley biotech developing a kidney disease drug, launched today with a $54.5 million seed round.
Why it matters: The funding will support Renasant's lead program, which could enter clinical trials in "a couple years," Renasant CEO Emily Conley tells Axios Pro.
